Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
Cognition Therapeutics (NASDAQ: CGTX) has published results from the SEQUEL study of CT1812, their lead candidate for Alzheimer's disease treatment, in The Journal of Prevention of Alzheimer's Disease. The single-site study measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's after 29 days of treatment. CT1812-treated participants showed consistent trends of improvement across all prespecified EEG parameters, with significant changes in relative theta power and AEC-c, which assesses brain region connectivity.
The study suggests CT1812 may normalize brain wave patterns and facilitate communication between brain regions by protecting synapses as an Aβ oligomer antagonist. Treatment produced a reduction in global relative theta power across various brain regions and improved global alpha AEC-c. CT1812 was well-tolerated with mostly mild to moderate adverse events reported.
Cognition Therapeutics (NASDAQ: CGTX) ha pubblicato i risultati dello studio SEQUEL su CT1812, il loro candidato principale per il trattamento dell'Alzheimer, sulla rivista The Journal of Prevention of Alzheimer's Disease. Lo studio, condotto in un'unica sede, ha misurato i modelli delle onde cerebrali in 16 adulti con Alzheimer lieve-moderato dopo 29 giorni di trattamento. I partecipanti trattati con CT1812 hanno mostrato tendenze di miglioramento costanti in tutti i parametri EEG predefiniti, con cambiamenti significativi nella potenza theta relativa e nell'AEC-c, che valuta la connettività delle regioni cerebrali.
Lo studio suggerisce che CT1812 potrebbe normalizzare i modelli delle onde cerebrali e facilitare la comunicazione tra le regioni cerebrali proteggendo le sinapsi in quanto antagonista degli oligomeri Aβ. Il trattamento ha prodotto una riduzione della potenza theta relativa globale in diverse regioni cerebrali e ha migliorato l'AEC-c alpha globale. CT1812 è stato ben tollerato, con eventi avversi segnalati per lo più lievi a moderati.
Cognition Therapeutics (NASDAQ: CGTX) ha publicado los resultados del estudio SEQUEL sobre CT1812, su candidato principal para el tratamiento del Alzheimer, en The Journal of Prevention of Alzheimer's Disease. El estudio de un solo sitio midió los patrones de ondas cerebrales en 16 adultos con Alzheimer leve a moderado después de 29 días de tratamiento. Los participantes tratados con CT1812 mostraron tendencias de mejora consistentes en todos los parámetros de EEG preespecificados, con cambios significativos en la potencia theta relativa y AEC-c, que evalúa la conectividad entre las regiones cerebrales.
El estudio sugiere que CT1812 podría normalizar los patrones de ondas cerebrales y facilitar la comunicación entre regiones cerebrales al proteger las sinapsis como antagonista de los oligómeros Aβ. El tratamiento produjo una reducción en la potencia theta relativa global en varias regiones del cerebro y mejoró el AEC-c alfa global. CT1812 fue bien tolerado, con eventos adversos mayormente leves a moderados reportados.
Cognition Therapeutics (NASDAQ: CGTX)는 알츠하이머병 치료를 위한 주요 후보 물질 CT1812의 SEQUEL 연구 결과를 The Journal of Prevention of Alzheimer's Disease에 발표했습니다. 이 단일 사이트 연구는 경도에서 중등도의 알츠하이머를 가진 16명의 성인에서 29일간의 치료 후 뇌파 패턴을 측정했습니다. CT1812 치료를 받은 참가자들은 모든 사전 지정 EEG 매개변수에서 일관된 개선 경향을 보였으며, 상대적인 세타 파워와 뇌 영역 연결성을 평가하는 AEC-c에서 유의미한 변화가 있었습니다.
이 연구는 CT1812가 뇌파 패턴을 정상화하고 시냅스를 보호하여 뇌 영역 간의 통신을 촉진할 수 있음을 시사합니다. 치료는 다양한 뇌 영역에서 전반적인 상대 세타 파워를 감소시키고 전반적인 알파 AEC-c를 향상시켰습니다. CT1812는 대부분 경미하거나 중등도의 부작용을 보고하였으며 잘 견딜 수 있었습니다.
Cognition Therapeutics (NASDAQ: CGTX) a publié les résultats de l'étude SEQUEL sur CT1812, leur principal candidat pour le traitement de la maladie d'Alzheimer, dans The Journal of Prevention of Alzheimer's Disease. L'étude, réalisée sur un seul site, a mesuré les modèles d'ondes cérébrales de 16 adultes souffrant de la maladie d'Alzheimer légère à modérée après 29 jours de traitement. Les participants traités avec CT1812 ont montré des tendances d'amélioration constantes dans tous les paramètres EEG prédéfinis, avec des changements significatifs dans la puissance theta relative et l'AEC-c, qui évalue la connectivité entre les régions du cerveau.
L'étude suggère que CT1812 pourrait normaliser les modèles d'ondes cérébrales et faciliter la communication entre les régions cérébrales en protégeant les synapses en tant qu'antagoniste des oligomères Aβ. Le traitement a entraîné une réduction de la puissance theta relative globale dans diverses régions cérébrales et a amélioré l'AEC-c alpha globale. CT1812 a été bien toléré, avec des événements indésirables rapportés pour la plupart légers à modérés.
Cognition Therapeutics (NASDAQ: CGTX) hat die Ergebnisse der SEQUEL-Studie zu CT1812, ihrem Hauptkandidaten zur Behandlung von Alzheimer, im The Journal of Prevention of Alzheimer's Disease veröffentlicht. Die Einrichtungsstudie maß die Gehirnwellenmuster bei 16 Erwachsenen mit leicht bis mäßig fortgeschrittener Alzheimer-Krankheit nach 29 Tagen der Behandlung. Die mit CT1812 behandelten Teilnehmer zeigten konstante Verbesserungen über alle vordefinierten EEG-Parameter hinweg, mit signifikanten Veränderungen in der relativen Theta-Leistung und AEC-c, welches die Konnektivität zwischen Gehirnregionen bewertet.
Die Studie deutet darauf hin, dass CT1812 Gehirnwellenmuster normalisieren und die Kommunikation zwischen den Gehirnregionen fördern könnte, indem es als Aβ-Oligomer-Antagonist die Synapsen schützt. Die Behandlung führte zu einer Reduktion der globalen relativen Theta-Leistung in verschiedenen Gehirnregionen und verbesserte die globale Alpha-AEC-c. CT1812 wurde gut vertragen, wobei überwiegend leichte bis moderate unerwünschte Ereignisse berichtet wurden.
- CT1812 showed consistent trends of improvement across all prespecified EEG parameters
- Significant changes observed in relative theta power (p=0.006) and AEC-c (p=0.034)
- CT1812 may normalize brain wave patterns and improve brain region connectivity
- Treatment reduced global relative theta power across various brain regions
- CT1812 was well-tolerated with mostly mild to moderate adverse events
- Small sample size of only 16 adults in the study
- Short treatment duration of 29 days
- Some adverse events reported, including diarrhea, nausea, and hepatic enzyme elevation
The publication of EEG findings from Cognition Therapeutics' Phase 2 SEQUEL study presents promising initial results for CT1812 in mild-to-moderate Alzheimer's disease. The study, while small (16 participants), showed consistent trends of improvement across all prespecified EEG parameters after just 29 days of treatment.
Key findings include:
- Significant change in relative theta power in the central brain region (p=0.006)
- Improved AEC-c, indicating better connectivity between brain regions (p=0.034)
- Consistent reduction in global relative theta power across various brain regions
- Improvement in global alpha AEC-c, potentially indicating normalized synaptic function
While encouraging, investors should note the small sample size and short duration of the study. Larger, longer-term trials will be important to confirm these initial findings and establish CT1812's efficacy in Alzheimer's treatment.
The SEQUEL study's EEG findings offer intriguing insights into CT1812's potential mechanism of action in Alzheimer's disease. The observed shift from slower theta frequencies towards faster alpha frequencies is particularly noteworthy, as it counters the typical progression seen in Alzheimer's patients.
The improvement in AEC-c (amplitude envelope correlation) is especially promising. This measure of brain connectivity is highly predictive of cognitive function changes in Alzheimer's. The fact that CT1812 positively influenced this parameter suggests it may have a neuroprotective effect that could translate to cognitive benefits.
However, it's important to remember that EEG changes don't always directly correlate with clinical outcomes. While these results are encouraging, they should be viewed as supportive evidence rather than definitive proof of efficacy. Future studies should focus on linking these EEG changes to measurable cognitive improvements and daily functioning in larger patient populations.
Cognition Therapeutics' publication of the SEQUEL study results marks a positive step in the development of CT1812 for Alzheimer's disease. The data provides a scientific rationale for the drug's mechanism of action and supports further clinical investigation.
From an industry perspective, several points stand out:
- The unique mechanism of CT1812 as an Aβ oligomer antagonist differentiates it in a crowded Alzheimer's drug pipeline
- The oral administration of CT1812 could provide a significant advantage over injectable treatments
- The safety profile appears favorable, with no severe adverse events reported
However, investors should be cautious. While promising, these results are from a small, early-phase study. The Alzheimer's drug development landscape is notoriously challenging, with many candidates failing in later-stage trials. Cognition Therapeutics will need to demonstrate consistent efficacy and safety in larger, longer-duration studies to truly stand out in this competitive field.
PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company’s lead candidate for the treatment of Alzheimer’s disease, were published in The Journal of Prevention of Alzheimer's Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer’s disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region (p=0.006) of the brain and AEC-c* (p=0.034), which assesses the connectivity between brain regions.
"The gradual slowing of brain wave patterns and impaired connectivity that is a hallmark of Alzheimer’s disease is due to the loss of synapses, which are the connection points between neurons,” stated Anthony O. Caggiano, MD, PhD, chief medical officer and head of R&D at Cognition Therapeutics. “Quantitative qEEG is a sensitive method of measuring the electrical activity of neurons in the brain. The changes we observed across EEG parameters in SEQUEL may indicate that CT1812 is normalizing brain wave patterns and facilitating communication between different brain regions. We believe that CT1812 was able to rescue these early deficits by protecting synapses through its unique mechanism as an Aβ oligomer antagonist.”
In the SEQUEL study, treatment with once-daily oral CT1812 produced a consistent reduction in global relative theta power and in relative theta power in frontal, temporal, parietal, occipital and central brain regions. Increasing prominence of slower EEG frequencies (4-8 Hz) termed “theta” and a declining prominence of “alpha” frequencies (8-12 Hz) are associated with cognitive decline in people with Alzheimer's disease. This improvement in global and relative theta power was coupled with an observed improvement in global alpha AEC-c, a measure of connectivity between brain regions, which has been found to be highly predictive of changes in cognitive function in Alzheimer’s disease. Together, the improvement in AEC-c and the shift in brain wave from theta towards faster alpha frequencies we believe supports our thesis that CT1812 has a unique neuroprotective mechanism that may normalize synaptic function.
CT1812 was observed to be well tolerated with mild or moderate treatment emergent adverse events (TEAEs) occurring in 11 patients in the CT1812-treated arm and 6 on placebo. The six treatment-related AEs were diarrhea, nausea, and vomiting with placebo; diarrhea, nausea, and hepatic enzyme elevation with CT1812. No AEs lead to discontinuation and no severe or serious AEs or deaths were reported among CT1812-treated participants.
These results and other details of the study may be found in the open-access article in The Journal of Prevention of Alzheimer's Disease, titled “A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease.” This and Cognition’s other published articles may be found on the Company’s Publication webpage.
* Note: AEC-c = corrected amplitude envelope correlation
About the SEQUEL Study
The SEQUEL study enrolled 16 adults (15 of whom completed the study) with mild-to-moderate Alzheimer’s disease (MMSE 18-26), each of whom were randomized to receive either 300mg CT1812 or placebo once daily for 29 days. After a 14-day wash-out period, participants cross over into the other treatment arm for an additional 29 days. Quantitative EEG evaluations were taken periodically throughout the duration of the trial. SEQUEL was designed to assess the safety and efficacy of CT1812 and to measure the impact of CT1812 on the electrical activity in the brain, specifically those electrical impulses in the theta band.
SEQUEL was supported by
About CT1812
CT1812 is an experimental orally delivered small molecule oligomer antagonist that penetrates the blood-brain barrier and binds selectively to the sigma-2 (σ-2) receptor complex. Preclinical and clinical data demonstrate that this binding results in the displacement of toxic Aβ oligomers. The σ-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with Aβ oligomers, oxidative stress and other stressors. This damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and Alzheimer’s disease progression.
Participants are currently being recruited in the START study (NCT05531656) of CT1812 in adults with early Alzheimer’s disease; and the MAGNIFY study (NCT05893537) in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration. Enrollment has completed in the SHIMMER study (NCT05225415) of CT1812 in adults with dementia with Lewy bodies and the aforementioned SHINE Study.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
FAQ
What were the key findings of Cognition Therapeutics' SEQUEL study for CT1812 (CGTX)?
How does CT1812 potentially benefit Alzheimer's patients according to the SEQUEL study results (CGTX)?
What was the safety profile of CT1812 in the SEQUEL study for Alzheimer's disease (CGTX)?
What is the significance of the EEG changes observed in the SEQUEL study of CT1812 (CGTX)?
